Public Employees Retirement System of Ohio Makes New Investment in Kura Oncology, Inc. $KURA

Public Employees Retirement System of Ohio bought a new stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 56,640 shares of the company’s stock, valued at approximately $621,000. Public Employees Retirement System of Ohio owned 0.06% of Kura Oncology at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Kura Oncology by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock worth $333,000 after buying an additional 2,977 shares during the period. Strs Ohio acquired a new position in Kura Oncology in the first quarter valued at approximately $143,000. Legal & General Group Plc lifted its holdings in Kura Oncology by 35.1% in the second quarter. Legal & General Group Plc now owns 72,910 shares of the company’s stock valued at $421,000 after buying an additional 18,930 shares during the period. Rhumbline Advisers boosted its stake in Kura Oncology by 13.0% in the second quarter. Rhumbline Advisers now owns 118,896 shares of the company’s stock valued at $686,000 after acquiring an additional 13,690 shares during the last quarter. Finally, American Century Companies Inc. boosted its stake in Kura Oncology by 244.5% in the second quarter. American Century Companies Inc. now owns 232,752 shares of the company’s stock valued at $1,343,000 after acquiring an additional 165,189 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have commented on KURA. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a research report on Monday, August 24th. Wedbush increased their target price on Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Thursday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a research report on Friday, July 17th. Oppenheimer set a $24.00 price target on shares of Kura Oncology in a research report on Thursday, May 28th. Finally, Wells Fargo & Company set a $24.00 price objective on shares of Kura Oncology in a report on Thursday, June 4th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Kura Oncology presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.40.

Insider Activity at Kura Oncology

In other news, insider Mollie Leoni sold 84,929 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the completion of the transaction, the insider owned 182,345 shares in the company, valued at $1,790,627.90. This represents a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Troy Wilson acquired 100,000 shares of the stock in a transaction dated Monday, August 24th. The shares were bought at an average cost of $12.39 per share, with a total value of $1,239,000.00. Following the transaction, the chief executive officer directly owned 479,194 shares of the company’s stock, valued at $5,937,213.66. This represents a 26.37% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders sold 120,761 shares of company stock worth $1,283,346. Corporate insiders own 7.60% of the company’s stock.

Key Headlines Impacting Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: Diabetes program spun out with $50 million in funding: Kura launched Caspian Therapeutics as a separately financed company to develop KO-7246, a menin inhibitor intended to stimulate pancreatic beta-cell expansion and endogenous insulin production in Type 1 and Type 2 diabetes. The financing was led by BVF Partners and included Eli Lilly, the T1D Fund, Invus, Montanova, Kura, and biotech executives. Kura Oncology launches Caspian Therapeutics with $50 million financing
• Positive Sentiment: Kura retains substantial upside exposure: The oncology company will retain approximately half of Caspian on a fully diluted basis while the subsidiary funds development independently, allowing Kura to participate in potential value creation without bearing all development costs. Preclinical data will be presented at the European Association for the Study of Diabetes meeting on September 29, 2026. Kura creates Lilly-backed spinout
• Neutral Sentiment: New CFO appointed: Jennifer Fulk became Kura’s chief financial officer on September 8. Her background includes biopharmaceutical finance, capital allocation, research and development portfolio management, commercial operations, and investor relations. Kura Oncology appoints Jennifer Fulk as chief financial officer
• Negative Sentiment: Execution risk remains: Caspian’s opportunity is based on preclinical findings, and KO-7246 still needs to demonstrate safety and efficacy in human trials. Investors may therefore remain cautious until the program produces clinical proof of concept.

Kura Oncology Trading Down 3.4%

NASDAQ KURA opened at $12.09 on Thursday. The firm has a market cap of $1.08 billion, a P/E ratio of -3.59 and a beta of 0.44. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 4.71. The stock’s 50-day moving average is $11.21 and its 200-day moving average is $9.91. Kura Oncology, Inc. has a one year low of $7.36 and a one year high of $13.90.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The business had revenue of $20.87 million during the quarter, compared to analyst estimates of $20.16 million. Sell-side analysts anticipate that Kura Oncology, Inc. will post -3.25 earnings per share for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.